Form 4: Axsome Therapeutics Director Roger Jeffs Receives New Equity Compensation

Axsome Therapeutics, Inc. Director Roger Jeffs was granted 3,166 stock options and 1,429 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Summary

• Roger Jeffs, a Director of Axsome Therapeutics, Inc. (AXSM), reported the acquisition of derivative securities.
• The filing indicates the grant of 3,166 stock options with an exercise price of $111.91 per share.
• Additionally, Mr. Jeffs was granted 1,429 Restricted Stock Units (RSUs), where each RSU represents a contingent right to receive one share of common stock.
• Both the stock options and RSUs were granted on June 6, 2025.
• The stock options are exercisable immediately upon grant and have an expiration date of June 6, 2035.
• Both the stock options and RSUs are scheduled to vest in full on the one-year anniversary of the grant date, specifically June 6, 2026.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a positive for aligning management interests with shareholders but does not indicate significant operational or financial news.

Positives

• The grant of stock options and restricted stock units to Director Roger Jeffs aligns his financial interests directly with the long-term performance and shareholder value of Axsome Therapeutics.
• Equity compensation is a standard practice for retaining and incentivizing key board members in publicly traded companies.

Future Outlook

The granted stock options and restricted stock units are set to vest on June 6, 2026, indicating a future date when these equity awards will become fully owned by the director.

Industry Context

The grant of equity compensation, such as stock options and restricted stock units, to non-employee directors is a common and widely accepted practice across various industries, including the biotechnology and pharmaceutical sectors where Axsome Therapeutics operates. This method is used to attract, retain, and incentivize board members by linking their compensation to the company's stock performance, thereby aligning their interests with those of long-term shareholders.

Comparison to Industry Standards

• The practice of granting equity compensation to directors is standard across publicly traded companies, including those in the pharmaceutical and biotechnology sectors like Axsome Therapeutics.
• While the specific number of options and RSUs granted varies based on company size, director responsibilities, and compensation philosophy, the structure of a one-year vesting period for annual grants is common.
• Companies such as Biogen Inc. (BIIB) and Vertex Pharmaceuticals Inc. (VRTX) also utilize similar equity-based compensation structures for their non-executive directors to foster alignment with shareholder interests.

Corporate Governance

Related Party Transactions

• The grant of stock options and restricted stock units to Roger Jeffs, a Director of Axsome Therapeutics, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's incentives with shareholder value creation, as the value of his compensation is tied to the company's stock performance.
• Employees: No direct impact on employees is indicated by this specific filing, which focuses on director compensation.

Next Steps

• The stock options and restricted stock units will vest on June 6, 2026, at which point they will become fully owned by Roger Jeffs.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Transaction, Director Compensation, Stock Option, Restricted Stock Units, Equity Grant, Corporate Governance